Clinical Trial

FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma

Study acronym: FET PET in HGG
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \[18F\]FET-PET in delineating disease. The main question\[s\] it aims to answer are: * whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression * whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-07.
Status change: Not Yet Recruiting → Recruiting 2024-11-28
Trial Details
NCT Number NCT06172595
Lead Sponsor Singapore General Hospital
Collaborators: National Cancer Centre, Singapore, National Neuroscience Institute Singapore, Duke-NUS Graduate Medical School
Conditions Glioma, Malignant
Enrollment 22 participants
Start Date 2023-12-21
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2024-12-03